Clinical trial
Effect of Natalizumab (Tysabri®) on Remyelination in Patients With Relapsing-remitting Multiple Sclerosis. A Follow-up Voxel-wise Magnetization Transfer Imaging Study.
NCT00937677 is registered in ClinicalTrials.gov with University at Buffalo as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Effect of Natalizumab (Tysabri®) on Remyelination in Patients With Relapsing-remitting Multiple Sclerosis. A Follow-up Voxel-wise Magnetization Transfer Imaging Study.
- Lead sponsor
- University at Buffalo
- Phase
- Observational
- Overall status
- Completed
- Start date
- November 30, 2007
- Completion date
- November 30, 2010
- Enrollment
- 85 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.